Hysiology and pathology from the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative issues. J Neurovirol 5: 538555. two. Lee J-H, Hua Lu H Chimeric p53 as an alternative therapy for hypoxic tumors. Cancer Biol Ther. 11: 108110. 3. Hdeib A, Sloan AE Convection-enhanced delivery of 131I-chTNT-1/B mAB for therapy of high-grade adult gliomas. Expert Opin Biol Ther. 11: 799806. four. Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK Convectionenhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat.; 5: 23950. five. Choi JJ, Feshitan JA, Baseri B, Wang S, Tung YS, et al. Microbubble-size dependence of focused ultrasound-induced blood-brain barrier opening in mice in vivo. IEEE Trans Biomed Eng. 57: 14554. six. Groothuis DR The blood-brain and blood-tumor barriers: a evaluation of methods for escalating drug delivery. Neuro Oncol. 2: 4559. 7. Siegal T, Zylber-Katz E Methods for escalating drug delivery for the brain: focus on brain lymphoma. Clin Pharmacokinet. 41: 17186. 8. Bellavance MA, Anlotinib site Blanchette M, Fortin D Recent advances in blood-brain barrier disruption as a CNS delivery tactic. AAPS J.; 10: 16677. 9. Steeg PS, Camphausen KA Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer. 11: 35263. ten. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, et al. Transferrin receptor on endothelium of brain capillaries. Nature; 312: 162163. 11. Zlokovic BV, Jovanovic S, Miao W, Samara S, Verma S, et al. Differential regulation of leptin transport by the choroid plexus and blood-brain barrier and higher affinity transport systems for entry into hypothalamus and across the 1379592 blood-cerebrospinal fluid barrier. Endocrinology. 141: 14341441. 12. Spencer BJ, Verma IM Targeted delivery of proteins across the bloodbrain barrier. Proc Natl Acad Sci U S A. 104: 75947599. 13. Wang D, El-Amouri SS, Dai M, Kuan C-Y, Hui DY, et al. Engineering a lysosomal enzyme having a derivative of receptor-binding domain of apoE enables delivery across the bloodbrain barrier. PNAS 110: 29993004. 14. Boado RJ, Hui EK, Lu JZ, Pardridge WM Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther. 333: 961969. 15. Deeken JF, Loscher W The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 13: 16631674. 16. Dietz GP, Bahr M Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci. 27: 85131. 17. Karkan D, Pfeifer C, Vitalis TZ, Arthur G, Ujiie M, et al. A distinctive carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS A single. 3: e2469. 18. Schwarze SR, Ho A, Vocero-Akbani 
A, Dowdy SF In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 15691572. 19. Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, et al. Extremely penetrative, drug-loaded nanocarriers increase therapy of glioblastoma. Proc Natl Acad Sci U S A. 110: 117516. 20. Allard E, Passirani C, Benoit JP Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 30: 230218. 21. Sarkar G, Curran GL, Mahlum E, Decklever T, Wengenack TM, et al. A carrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM towards the brain. PLoS One particular. six: e28881. 22. Carlson SK, GNF-7 site Classic KL, Hadac EM, Bender CE, Kemp.Hysiology and pathology on the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative problems. J Neurovirol five: 538555. two. Lee J-H, Hua Lu H Chimeric p53 as an option therapy for hypoxic tumors. Cancer Biol Ther. 11: 108110. three. Hdeib A, Sloan AE Convection-enhanced delivery of 131I-chTNT-1/B mAB for treatment of high-grade adult gliomas. Expert Opin Biol Ther. 11: 799806. four. Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK Convectionenhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat.; five: 23950. 5. Choi JJ, Feshitan JA, Baseri B, Wang S, Tung YS, et al. Microbubble-size dependence of focused ultrasound-induced blood-brain barrier opening in mice in vivo. IEEE Trans Biomed Eng. 57: 14554. six. Groothuis DR The blood-brain and blood-tumor barriers: a review of approaches for increasing drug delivery. Neuro Oncol. two: 4559. 7. Siegal T, Zylber-Katz E Strategies for escalating drug delivery for the brain: concentrate on brain lymphoma. Clin Pharmacokinet. 41: 17186. eight. Bellavance MA, Blanchette M, Fortin D Current advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J.; ten: 16677. 9. Steeg PS, Camphausen KA Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer. 11: 35263. ten. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, et al. Transferrin receptor on endothelium of brain capillaries. Nature; 312: 162163. 11. Zlokovic BV, Jovanovic S, Miao W, Samara S, Verma S, et al. Differential regulation of leptin transport by the choroid plexus and blood-brain barrier and high affinity transport systems for entry into hypothalamus and across the 1379592 blood-cerebrospinal fluid barrier. Endocrinology. 141: 14341441. 12. Spencer BJ, Verma IM Targeted delivery of proteins across the bloodbrain barrier. Proc Natl Acad Sci U S A. 104: 75947599. 13. Wang D, El-Amouri SS, Dai M, Kuan C-Y, Hui DY, et al. Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the bloodbrain barrier. PNAS 110: 29993004. 14. Boado RJ, Hui EK, Lu JZ, Pardridge WM Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther. 333: 961969. 15. Deeken JF, Loscher W The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 13: 16631674. 16. Dietz GP, Bahr M Delivery of bioactive molecules in to the cell: the Trojan horse strategy. Mol Cell Neurosci. 27: 85131. 17. Karkan D, Pfeifer C, Vitalis TZ, Arthur G, Ujiie M, et al. A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS One. 3: e2469. 18. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF In vivo protein transduction: delivery of a biologically active protein in to the mouse. Science 285: 15691572. 19. Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, et al. Very penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proc Natl Acad Sci U S A. 110: 117516. 20. Allard E, Passirani C, Benoit JP Convection-enhanced delivery of nanocarriers for the remedy of brain tumors. Biomaterials 30: 230218. 21. Sarkar G, Curran GL, Mahlum E, Decklever T, Wengenack TM, et al. A carrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM for the brain. PLoS 1. 6: e28881. 22. Carlson SK, Classic KL, Hadac EM, Bender CE, Kemp.